ArticleEuropean journal of medical research2025
Metabolic dysfunction-associated fatty liver disease and the risk of gout: a UK Biobank prospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome-wide association and polygenic risk score analyses of MASLD-related hepatic steatosis severity in a Taiwanese Han population.Cell & bioscience · 2026Article
- Metabolic characteristics and risk profile of non-obese fatty liver disease in an elderly Chinese community cohort.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGout, an inflammatory arthritis characterized by monosodium urate crystal deposition, affects 1-4% of the global population and demonstrates strong associations with metabolic syndrome. Metabolic dysfunction-associated fatty liver disease (MASLD), affecting 38% of adults worldwide, represents a multisystem disorder with substantial morbidity and mortality. This first European prospective cohort study systematically examines the association between MASLD and incident gout risk.
methodUtilizing UK Biobank data (n = 402,083 after exclusions), we conducted a prospective cohort analysis excluding participants with baseline gout, arthritis, hepatitis B/C, alcohol-related liver disease, or events within the initial 2-year follow-up. Cox proportional hazards models evaluated MASLD-gout associations, with Kaplan-Meier curves illustrating cumulative incidence.
resultMASLD patients exhibited a 71% elevated gout risk versus non-MASLD counterparts (HR = 1.71, 95% CI 1.59-1.83, P < 0.0001). Subgroup analyses revealed consistent associations across demographics, with attenuated risk in older adults (≥ 65 years: HR = 1.55 vs. < 65 years: HR = 1.86). Paradoxically, individuals without diabetes, hypertension, or central obesity demonstrated a higher gout risk than those with these comorbidities. MASLD patients showed significantly greater cumulative gout incidence over time (P < 0.001).
conclusionMASLD independently associates with increased gout risk, persisting after comprehensive confounder adjustment. These findings underscore MASLD's potential role in gout pathogenesis and highlight the clinical relevance of targeted MASLD interventions for gout prevention. Mechanistic and causal investigations remain warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.